阿奇霉素群体给药后的抗菌药物耐药性监测策略
本文讨论阿奇霉素群体给药(MDA)用于降低儿童死亡率时可能筛选出多重耐药病原体,现有证据提示反复MDA可导致肠道和呼吸道细菌对大环内酯类等抗生素耐药持续增加。作者建议在MDA实施全程开展针对关键抗生素(尤其是WHO Access组)的短期和长期耐药监测,并采用基因型方法克服指示菌耐药监测的局限。
要点
- 阿奇霉素MDA可能筛选多重耐药病原体,反复给药或致肠道和呼吸道细菌耐药持续增加。
- 现有证据多来自限时干预的标准微生物学技术,长期反复MDA需不同监测策略。
- 建议全程监测关键抗生素(尤其WHO Access组)耐药,采用基因型方法。
核心结论
- 阿奇霉素MDA可能筛选多重耐药病原体,反复给药或致肠道和呼吸道细菌对大环内酯类等抗生素耐药持续增加。
- 需在MDA实施全程对关键抗生素(尤其WHO Access组)开展短期和长期耐药监测,并采用基因型方法。
研究设计与样本
- 本文为述评/综述类文章,基于近期大型随机对照试验及现有微生物学监测证据进行讨论。
主要发现
- 试验显示阿奇霉素MDA可降低儿童死亡率,但可能筛选多重耐药病原体。
- 证据提示反复阿奇霉素MDA可导致肠道和呼吸道细菌对大环内酯类及其他抗生素耐药持续增加。
- 现有证据来自标准微生物学技术且聚焦限时干预,长期反复MDA需不同监测策略。
临床怎么用
- 在阿奇霉素MDA实施全程监测关键抗生素(尤其WHO Access组)耐药。
- 采用基因型方法监测耐药,以克服指示菌耐药监测的局限。
- 开展短期和长期耐药监测以评估公共卫生影响。
局限性
- 现有证据来自标准微生物学技术和限时干预研究,可能不适用于长期反复MDA。
- 指示菌耐药监测存在局限性,需基因型方法补充。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The reduction in childhood mortality noted in trials investigating azithromycin mass drug administration (MDA) for trachoma control has been confirmed by a recent large randomized controlled trial. Population-level implementation of azithromycin MDA may lead to selection of multiresistant pathogens. Evidence suggests that repeated azithromycin MDA may result in a sustained increase in macrolide and other antibiotic resistance in gut and respiratory bacteria. Current evidence comes from standard microbiological techniques in studies focused on a time-limited intervention, while MDA implemented for mortality benefits would likely repeatedly expose the population over a prolonged period and may require a different surveillance approach. Targeted short-term and long-term surveillance of resistance emergence to key antibiotics, especially those from the World Health Organization Access group, is needed throughout any implementation of azithromycin MDA, focusing on a genotypic approach to overcome the limitations of resistance surveillance in indicator bacteria.
引用
- Mack I, Sharland M, Berkley JA, et al. Antimicrobial Resistance Following Azithromycin Mass Drug Administration: Potential Surveillance Strategies to Assess Public Health Impact. Clin Infect Dis. 2020. PMID: 31633161. doi:10.1093/cid/ciz893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。